Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Gallium Citrate Imaging in HCC
NCT03116945Phase 2Unknown
- Sponsor
- Rutgers University
- Start
- Jun 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium-68 citrate in hepatocellular carcinoma (HCC), sponsored by Rutgers University. Primary endpoint: Uptake of positron emitting radiotracer, 68Gallium Citrate at 1 year. Status: unknown.
02
Drugs
gallium-68 citrate
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03116945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116945.